We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety profile of tofacitinib in rheumatoid arthritis: a single-center experience.
- Authors
Akca, Tolgahan; Demir, Ceren; Sargın, Gökhan; Çildağ, Songül; Şentürk, Taşkın
- Abstract
Objective: To assess the adverse events (AEs) of tofacitinib in rheumatoid arthritis (RA) patients and to present real-life experiences. Methods: Data on the demographic characteristics, comorbidities, and the AEs of 71 RA patients using tofacitinib was collected. Coronary artery disease, cerebrovascular disease, pulmonary embolism, malignancy, and mortality were defined as serious AEs. The risk factors for serious AEs were defined. Results: Infections were the most common drug-related AEs, most of which were upper respiratory and urinary tract infections. Malignancy was detected in 3 patients in follow-up. No significant difference was found in the rates of overall AEs except urinary tract infections, between patients <65 years and those =65 years of age. However, serious AEs were observed more frequently in patients aged =65 years (p=0.019). Older age, male gender, pre-existing hyperlipidemia, and the initial year of tofacitinib treatment were significantly associated with developing serious AEs. Four patients (median age= 65.9 years) died. Conclusion: Real-life data on the safety profile of tofacitinib in RA was presented in this study. Male gender was an independent risk factor for serious AEs in subjects receiving tofacitinib. Patients with older age, male gender, those with hyperlipidemia, and those in their first year of treatment should also be closely monitored for serious AEs.
- Subjects
RHEUMATOID arthritis; HYPERLIPIDEMIA; URINARY tract infections; MORTALITY; CEREBROVASCULAR disease
- Publication
Journal of Turkish Society for Rheumatology, 2024, Vol 16, Issue 1, p25
- ISSN
2651-2653
- Publication type
Article
- DOI
10.4274/raed.galenos.2023.41636